Oral Selenium Therapy for the Prevention of Mucositis
Launched by TEHRAN UNIVERSITY OF MEDICAL SCIENCES · Sep 12, 2011
Trial Information
Current as of July 25, 2025
Unknown status
Keywords
ClinConnect Summary
Patients with AML or ALL diagnosis, candidates for high dose chemotherapy with stem cell transplantation will be screened for enrollment in the study.
Patients will be randomized in two groups with balanced block randomization method. One group will receive selenium tablet twice per day and another group will receive placebo two times per day.Therapy will start on the morning before starting chemotherapy and will continue until the first of either discharge day or day +21.
Response assessment will include:
1. Mucositis assessment using WHO grading and OMAS scores- to be done from baselin...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with AML or ALL undergoing high dose chemotherapy with stem cell transplantation
- • Adequate renal and hepatic function
- Exclusion Criteria:
- • Taking selenium supplement before admission
About Tehran University Of Medical Sciences
Tehran University of Medical Sciences (TUMS) is a prestigious institution dedicated to advancing healthcare through innovative research and education. As a leading clinical trial sponsor, TUMS is committed to conducting high-quality, ethically sound clinical research that contributes to the understanding and treatment of various medical conditions. With a strong emphasis on collaboration and interdisciplinary approaches, TUMS harnesses the expertise of its diverse faculty and state-of-the-art facilities to facilitate groundbreaking studies that aim to improve patient outcomes and enhance public health. Through its rigorous oversight and adherence to regulatory standards, TUMS ensures the integrity and reliability of its clinical trials, fostering trust and transparency in the research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Molouk Hadjibabaie, Pharma D
Study Chair
Tehran University of Medical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials